ONWARD Medical (ONWD) is a publicly traded Spinal & Peripheral Interfaces company founded in 2014 and based in Eindhoven, Netherlands.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Oct 21, 2021 | IPO | $89.6M | $430M | — |
| Apr 22, 2021 | Growth | $32M | — |
| Invest-NL |
| Apr 1, 2016 | Growth | $29M | — | LSP Life Sciences |
No articles ingested yet for ONWARD Medical. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
The first FDA-approved non-invasive external spinal cord stimulation system for people with chronic spinal cord injury, launched in the U.S. in December 2024. Delivers targeted electrical pulses to the spinal cord through skin-surface electrodes, enabling enhanced voluntary movement during rehabilitation sessions. Used in clinical and outpatient settings without surgery.
An investigational fully-implantable spinal cord stimulation system designed to restore walking and upper-limb function in people with spinal cord injury. Delivers epidural electrical stimulation (EES) to the lumbosacral spinal cord in synchrony with voluntary effort. Based on the EPFL-derived science that demonstrated paralyzed patients walking in pivotal human trials.
An investigational brain-computer interface platform that pairs cortical recording with ARC spinal stimulation to create a digital bridge from brain to spine, restoring volitional movement in paralyzed patients. Builds on ONWARD's first five successful BCI implants completed by May 2025, targeting both upper- and lower-limb restoration.
10 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗